Global Patient Derived Xenograft & PDX Models Market Growth (Status and Outlook) 2023-2029

Global Patient Derived Xenograft & PDX Models Market Growth (Status and Outlook) 2023-2029

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.

LPI (LP Information)' newest research report, the “Patient Derived Xenograft & PDX Models Industry Forecast” looks at past sales and reviews total world Patient Derived Xenograft & PDX Models sales in 2022, providing a comprehensive analysis by region and market sector of projected Patient Derived Xenograft & PDX Models sales for 2023 through 2029. With Patient Derived Xenograft & PDX Models sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Patient Derived Xenograft & PDX Models industry.

This Insight Report provides a comprehensive analysis of the global Patient Derived Xenograft & PDX Models landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Patient Derived Xenograft & PDX Models portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Patient Derived Xenograft & PDX Models market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Patient Derived Xenograft & PDX Models and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Patient Derived Xenograft & PDX Models.

The global Patient Derived Xenograft & PDX Models market size is projected to grow from US$ 324.4 million in 2022 to US$ 586.1 million in 2029; it is expected to grow at a CAGR of 8.8% from 2023 to 2029.

Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.

This report presents a comprehensive overview, market shares, and growth opportunities of Patient Derived Xenograft & PDX Models market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Mice Models
Rat Models

Segmentation by application
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead

Please note: The report will take approximately 2 business days to prepare and deliver.